Elevated levels of IGF-1 have been associated with an increased risk of certain cancers, such as breast, prostate cancer, and colorectal cancers, in some studies
4 Clinical evidence In adults with obesity, 72 weeks of orforglipron treatment resulted in greater body-weight reductions than placebo, up to -11.2%, compared to -2.1% with placebo
Data analysis showed that the two groups were homogeneous in terms of demographic characteristics and baseline laboratory tests and severity of PCOS
1 If approved, an effective once-daily oral GLP-1 could significantly expand access by lowering delivery barriers, improving adherence for injection-averse patients, and alleviating distribution constraints often associated with injectable formulations
By the end of this article, you will understand not just the "how" of mixing these two ingredients, but the "why" behind their powerful interaction